Biocause Pharma(SZ:000627)2018-10-31 16:00Financial Performance - Net profit attributable to shareholders decreased by 22.77% year-on-year to ¥164.52 million for the reporting period[8]. - Operating revenue for the reporting period was ¥4.04 billion, down 51.73% compared to the same period last year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥128.93 million, a decrease of 39.48% year-on-year[8]. - Basic earnings per share for the reporting period was ¥0.03, a decline of 40.00% compared to the same period last year[8]. - The weighted average return on net assets was 0.87%, down 0.66 percentage points year-on-year[8]. - The company reported a significant increase in comprehensive income total for the current period is CNY -159,000,882.30, compared to CNY 999,879,019.07 in the previous period[43]. - Total operating revenue for the current period is CNY 4,040,985,879.35, a decrease of 51.8% compared to CNY 8,372,168,005.49 in the previous period[40]. - Net profit for the current period is CNY 303,668,369.44, a decrease of 31.2% compared to CNY 441,435,910.29 in the previous period[42]. - Total operating revenue for the period was CNY 24,199,852,946.35, a decrease of 48.2% compared to CNY 46,588,730,805.57 in the previous period[48]. - Net profit for the period reached CNY 1,774,267,571.83, an increase of 4.3% from CNY 1,701,834,315.19 in the same period last year[51]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥163.67 billion, an increase of 16.56% compared to the end of the previous year[8]. - Total liabilities rose to CNY 138.08 billion, up from CNY 113.71 billion, indicating an increase of about 21.4%[34]. - The company's equity attributable to shareholders decreased to CNY 18.84 billion from CNY 19.34 billion, a decline of approximately 2.6%[34]. - Total current assets increased to CNY 37.38 billion from CNY 27.39 billion, reflecting a growth of approximately 36.5%[32]. - Non-current assets totaled CNY 126.29 billion, up from CNY 113.02 billion, marking an increase of about 11.7%[32]. - The company's total liabilities to equity ratio increased, indicating a higher leverage position[34]. Cash Flow - The company reported a net cash flow from operating activities of ¥8.78 billion, a decrease of 2.50% compared to the same period last year[8]. - Cash and cash equivalents decreased significantly to CNY 3.48 billion from CNY 11.17 billion, a decline of approximately 68.8%[31]. - Cash inflow from operating activities is 35,487,957,761.22, down from 41,193,407,121.75 in the previous period[58]. - Cash outflow from operating activities totals 26,708,373,964.95, compared to 32,188,411,414.23 in the previous period[58]. - The ending balance of cash and cash equivalents is 3,465,963,502.19, down from 7,444,003,396.29 in the previous period[59]. - The net cash flow from operating activities was -232,151,308.75 CNY, a significant decrease compared to 22,658,614.41 CNY in the previous period[60]. Shareholder Information - The total number of shareholders at the end of the reporting period was 91,162[12]. - The largest shareholder, New Liyi Group Co., Ltd., held 37.00% of the shares, amounting to 1,827,970,487 shares[12]. - The top ten shareholders did not engage in any repurchase transactions during the reporting period[14]. Research and Development - Research and development expenses increased to CNY 3,570,644.40, up 70.5% from CNY 2,097,163.56 in the previous period[42]. - Research and development expenses were CNY 7,339,606.91, slightly up from CNY 6,126,117.05, indicating a year-over-year increase of 19.8%[50]. Non-Recurring Items - Non-recurring gains and losses amounted to ¥215.73 million, primarily from the disposal of non-current assets and government subsidies[10]. - The company reported a foreign exchange gain of CNY 1,389,995.83, compared to a loss of CNY 741,878.96 in the previous period[41].